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ABSTRACT 
Heroin users/injectors’ risk of drugs-related death by sex and current age is weakly 
estimated both in individual cohorts of under 1000 clients, 5000 person-years or 50 
drugs-related deaths and when using cross-sectional data.  
 
A workshop in Cambridge analysed six cohorts who were recruited according to a 
common European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
protocol from drug treatment agencies in Barcelona, Denmark, Dublin, Lisbon, Rome 
and Vienna in the 1990s; and, as external reference, opiate-user arrestees in France 
and hepatitis C diagnosed ever-injectors in Scotland in 1993-2001, both followed by 
database linkage to December 2001.  
  
EMCDDA cohorts recorded approximately equal numbers of drugs-related deaths 
(864) and deaths from other non-HIV causes (865) during 106,152 person-years of 
follow-up. External cohorts contributed 376 drugs-related deaths (Scotland 195, 
France 181) and 418 deaths from non-HIV causes (Scotland 221, France 197) during 
86,417 person-years of follow-up (Scotland 22,670, France 63,747). 
 
EMCDDA cohorts reported 707 drugs-related deaths in 81,367 man-years {8.7 per 
1000 person-years, 95% CI: 8.1 to 9.4} but only 157 in 24,785 person-years for 
females {6.3 per 1000 person-years, 95% CI: 5.4 to 7.4}.  
 
Except in external cohorts, relative risks by current age-group were not particularly 
strong, and more modest in Poisson regression than in cross-sectional analyses: 
relative risk was 1.2 (95% CI: 1.0-1.4) for 35-44 year olds compared to 15-24 year 
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olds, but 1.4 for males (95%CI: 1.2-1.6), and dramatically lower at 0.44 after the first 
year of follow-up (95% CI: 0.37-0.52). [242 words] 
 
Key words: drugs-related deaths, heroin users, injectors, sex, age-group, non-HIV 
mortality. 
 
Key-points: Back-calculating past injector incidence and projecting late sequelae of 
Hepatitis C should take into account that male injectors’ risk of drugs related death is 
1.4 times higher than for females. Drugs-related deaths account for half of all non-
HIV deaths among heroin users/injectors. Hazard of drugs-related death may be only 
moderately affected by current age. 
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INTRODUCTION   
Most European countries have national or regional registers which identify the 
deceased by name, postal address, sex and date of birth. Registers record date of death 
and code for cause of death according to the International Classification of Diseases 
(ICD). Heterogeneity in ICD codes used to classify ‘drugs-related deaths’ (Advisory 
Council on the Misuse of Drugs, 2000) has led the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA, 2000) to implement a standard classification 
to improve comparability. We adopt EMCDDA’s classification. 
 
Standardized in this way, routine mortality data give total numbers of drugs-related 
deaths by region, sex and age-group (Jackson, 2003; Jossels and Sartor, 2006), which 
can be related to a suitable reference population, either general (Uren et al., 2001; 
Quaglio et al., 2001; Jossels and Sartor, 2006) or, preferably, problem or injection 
drug users (see Hay et al., 2001; EMCDDA, 2003; Bird et al., 2003; Hickman et al., 
2004; King et al., 2005; King et al., 2008). Mortality studies in cohorts of problem 
drug users or injectors are arguably a better approach still (see Wahren et al., 1997; 
Versino et al., 2000; Langendam et al., 2001; Bargagli et al., 2001; Risser et al., 2001; 
Gossop et al., 2002; Hickman et al., 2003; Galai et al., 2003; Copeland et al., 2004; 
Bargagli et al., 2005; Bloor et al., 2008) because: a) they document not only drugs-
related but also HIV-related and other-cause mortality (see Darke and Ross, 2002 and  
Bloor et al., 2008), b) the covariate influences of sex and current age on the risk of 
drugs-related death can be estimated for individuals whose drugs history, including 
treatment referral (Buster et al., 2002 and Fugelstad et al., 2007), route of 
administration of primary drug and initiation age, was documented in a standardized 
manner at enrolment to the cohort (Hickman et al., 2003 and Copeland et al., 2004), 
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and c) with shared protocol for enrolment, comparably-estimated risks can be 
compared across cohorts.  
 
Bird et al. (2003), for example, applied evidence-synthesis techniques to published 
data from Scotland to deduce that the relative risk of drugs-related death per 100 
injectors could be 1.8 times as high for males (95% CI: 1.3 to 2.3) and two to six 
times higher for older injectors. Later, by accessing primary, but still cross-sectional, 
data King et al. (2005; 2008) revised these estimates down; and allowed for a sex by 
age-group interaction, as did Copeland et al.(2004) in their Edinburgh cohort. In this 
paper, we study the relative risk of drugs-related death by sex and older age in major 
cohorts, rather than by synthesis of cross-sectional data. We also take epoch of 
follow-up into account since a client’s pattern of opiate use may change – without its 
having been necessarily documented - in the elapsed time since recruitment. 
  
A week-long analysis workshop was convened in Cambridge for representatives of 
eight major cohorts of European heroin users or injectors, see also Bargagli et al. 
(2005) and Bird and Hutchinson (2003). For drugs-related deaths, we used limited 
demographic data for individual patients and Poisson (or Cox) regression to assess the 
influence of sex, current age, epoch of follow-up, injector status at enrolment and time 
since start of heroin use. Six of the eight cohorts shared a common EMCDDA 
protocol (see also Bargagli et al., 2005) to recruit heroin users (among others) who 
presented at drug treatment agencies in Barcelona, Lisbon, Rome, Vienna, Dublin and 
throughout Denmark. For external reference, two other large cohorts, respectively of 
1992-93 and 1996-97 arrests in France for heroin use (or heroin use and trafficking) 
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and injection-related Hepatitis C diagnoses in Scotland in 1993-2001, were included 
as a check on generalising from cohorts recruited only at drug treatment agencies. 
 
Because large cohorts of heroin users or injectors - whether recruited at drug 
treatment agencies, as arrestees, or at the time of Hepatitis C diagnosis – are costly to 
maintain in individual follow-up (see Hickman et al., 2003 and Galai et al., 2003), the 
alternative of database linkage of client identifiers to the national (or regional) register 
of deaths can be used (see Bird and Hutchinson, 2003; Singleton et al., 2003; 
McDonald et al., 2008), as here, to establish clients’ date and cause of death. Unlike 
more intensively followed-up cohorts, which ascertain when clients subsequently 
become abstinent, were off-injecting, or dropped out of drugs rehabilitation (see 
Darke et al., 1996; Dettmer et al., 2000; Gossop et al., 2002; Preti et al., 2002; Buster 
et al., 2002; and Mattick and Degenhardt, 2003), or were incarcerated (see Bird and 
Hutchinson, 2003; Singleton et al., 2003; Seaman et al., 1998), these later events 
cannot be taken into account directly when follow-up is by database linkage. Instead, 
we checked indirectly on the persistence of enrolment characteristics by limiting 
follow-up to the first two years after enrolment in a sensitivity analysis.  
 
The workshop was convened because understanding how the risk of drugs-related 
death in heroin users or injectors depends on sex and current age is critically 
important both for back-calculation of the past incidence of injecting and for 
projecting the late sequelae of injection-related hepatitis C infection (Bird et al., 2001; 
Law et al., 2001; Law et al, 2003; De Angelis et al., 2004; Hutchinson et al., 2005).  
Our focus is on drugs-related and all non-HIV deaths because HIV prevalence in 
heroin users/injectors is highly variable between countries, but well studied - as is 
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HIV progression itself. We therefore provide precisely-estimated sex and age-
appropriate hazards of drugs-related death from EMCDDA and external reference 
cohorts.  
 
METHODS 
COSMO Workshop cohorts 
To enhance comparability across cohorts, eligibility was limited to enrolments in 
1990 or later of heroin users or injectors, and information was required on cause as 
well as date of death. Six EMCDDA cohorts were represented: see Bargagli et al. 
(2005) for additional background on individual EMCDDA cohorts. How 
representative of eligible clients at drug treatment centres the EMCDDA cohorts are is 
not reportable, because the proportion of invitees who declined to provide sufficient 
identifying information for follow-up by database linkage was never recorded.   
 
Confidential linkage of Scotland’s register of Hepatitis C diagnosed ever-injectors to 
its deaths register was based on master index (initial of first name, soundex of 
surname, gender and date of birth) because patient names are not recorded on 
Scotland’s Hepatitis C register (Surveillance, 2003). Enrolment date was set at 28 
days after the date of Hepatitis C diagnosis to exclude diagnoses made either post-
mortem or proximal to death. See McDonald et al. (2008) for cause-specific mortality 
follow-up on all Scotland’s Hepatitis C diagnoses. 
 
The eighth cohort was individuals arrested in France for heroin use (or heroin use and 
trafficking) in 1992, 1993, 1996 and 1997. Because only year of arrest was recorded 
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on the research database, enrolment date was forwarded to 1 January of the calendar 
year following the arrest year. 
 
COSMO Workshop classification of causes of death 
Underlying cause of death was classified as drugs-related or HIV-related by grouping 
ICD9 (or ICD10) codes as follows: 
 
Drugs-related 
Drug abuse (more precisely: mental and behavioural disorders due to use of  . . . ): 
ICD9:    292; 304.0 to 304.9; 305.2 to 305.9.   ICD10:  F11 to F16, F18 & F19. 
 
Accidental poisoning by drugs, medicaments and biological substances:  
ICD9*:    E850-E858.   ICD10:  X40 to X44 & X49. 
* In combination with N-codes (N965.0 to 965.9 & N969.0 to 969.9) which specify 
the nature of the injury. 
 
Intentional self-poisoning by drugs, medicaments and biological substances: 
ICD9*:   E950.0 to E950.5 & E950.9.    ICD10:  X60 to X64. 
 
Poisoning of undetermined intent by drugs, medicaments and biological substances: 
ICD9*:   E980.0 to E980.5 & E980.9.    ICD10:  Y10 to Y14 & Y19. 
 
Assault by drugs, medicaments and biological substances:  
ICD9*:   E962.0.   ICD10:  X85. 
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HIV-related 
ICD9:     042.0 to 044.9 & 279.1.   ICD10:   B20 to B24.  
 
Exceptionally, deaths which remained unclassified as to drugs-related, HIV-related or 
other causes are shown in Table 1 as ‘cause of death not known’. Sub-classifications 
of drugs-related deaths were not analysed. 
 
How COSMO Workshop operated 
Key data for analysis at COSMO Workshop were determined in advance so that 
analysis files could be brought in common format. In practice, the data management 
step, and associated checks, was not fully operational until the workshop’s third day, 
which encroached on analysis time and limited the scope for further data correction 
due to anomalies at analyses. Only one important data anomaly came to light after the 
COSMO Workshop, which had to be rectified at a later date. The workshop was 
organised into three writing-analysis teams with intended feedback between teams at 
the end of each working day, particularly to share data-management decisions. Even 
so, some residual disparities in coding conventions between teams have resulted in 
minor differences between papers in person-years of follow-up, different decisions on 
eligibility (for example, because this paper focuses on drugs-related mortality, the 
Danish cohort was limited to1997-99 recruits with follow-up to 31 December 1999 to 
minimise missing causes of death, see Bargagli et al. (2005)), and even some 
differences in classification of deaths. With one exception, see above, these have not 
been revisited because their impact is likely to be minor, and to do so would – in 
effect - require another workshop, but also because they reflect the reality that 
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common enrolment protocols need to be matched in future also by a common 
database with initially programmed data-checks. 
 
Statistical methods 
The time-scale most relevant for public health projections and back-calculation is the 
risk of drugs-related death (or all non-HIV deaths) according to current age of the 
heroin user/injector. Poisson regression was used to estimate drugs-related death risks 
according to sex, current-age band (under 25, 25-34, 35-44 years, with an imposed 
upper age-limit of 45 years) and follow-up epoch (half-year). Pooling of covariate 
influences across cohorts is reported for the two external cohorts [1], for clients 
enrolled at drug treatment agencies [2], and for all eight cohorts combined [3]. Results 
of a sensitivity analysis, in which the frailty of enrolment characteristics was checked 
by restricting follow-up to within two years, were qualitatively similar and are 
available from the authors.  
 
A second important time-scale is time since start of heroin/injector career, to 
understand whether any apparent increase in the risk of drugs-related death for older 
heroin users/injectors is genuinely an aging effect, or due to partial confounding of 
duration of heroin user/injector career with current age. Age at initiation to heroin use 
was available from four cohorts only (Barcelona, Lisbon, Rome and Denmark), and 
enabled proportional hazards regression modelling of whether the career-specific risk 
of drugs-related death increases when current age is over 34 years.  
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RESULTS 
Table 1 shows that the six 1990s-recruited EMCDDA cohorts from drug treatment 
agencies had effective last follow-up dates between end of May 1997 (Rome) and end 
of December 2001 (Barcelona and Lisbon), and accounted for approximately equal 
numbers of drugs related deaths (864) and deaths from specified other non-HIV 
causes (865) during 106,152 person-years of follow-up. There was, however, marked 
heterogeneity in the number of HIV-related deaths, which nearly equalled  - or 
exceeded - drugs-related deaths in Rome, Lisbon and Barcelona, but were otherwise 
mostly less than half the cohort’s number of drugs-related deaths, see also France’s 
heroin-user arrestees and Scotland’s hepatitis C diagnosed ever-injectors. These two 
external reference cohorts together contributed a further 376 drugs-related deaths 
(Scotland 195, France 181) and 418 deaths from specified other non-HIV causes 
(Scotland 221, France 197) during 86,417 person-years of follow-up (Scotland 
22,670, France 63,747). Table 1 shows that each cohort contributed at least 5,000 
person-years of follow-up within two years of enrolment, and the minimum number 
of drugs-related deaths was 34 (Dublin), 26 of which occurred in the first two years 
after enrolment. 
 
In all eight cohorts, 70% or more of clients (heroin users or ever-injectors) were male. 
Denmark’s heroin user cohort (restriction: with knowable cause of death) was 
recruited wholly in 1997 to 1999. The external reference cohorts related 
predominantly to enrolments in 1997 or later – 71% of Scotland’s hepatitis C 
diagnosed ever-injectors and 82% of France’s heroin-user arrestees – whereas three 
(Lisbon, Rome, Barcelona) of the six 1990s-recruited EMCDDA cohorts from drug 
treatment agencies related essentially to clients who enrolled before 1997.  
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Table 1 shows also that the eight analysed cohorts differed in the percentage of 
clients aged under 20 years at enrolment, which exceeded 10% only for Lisbon and 
Dublin, whereas Denmark’s heroin user cohort and Scotland’s hepatitis C diagnosed 
ever-injectors had the greatest representation of clients over 39 years of age at 
enrolment, respectively 24% and 9%. 
 
Because all cohorts were followed-up by database linkage, time-specific information 
about clients’ drug-dependence and injecting after enrolment was lacking. For greater 
comparability between cohorts, Table 1 therefore shows drugs-related deaths and 
person-years of follow-up within the first two years after enrolment, during which 
enrolment characteristics may be considered relatively apposite still.  
 
During the first two years of follow-up, the 1990s-recruited EMCDDA cohorts 
accounted for 475 drugs-related deaths and 46,868 person-years of follow-up; 
Scotland’s hepatitis C diagnosed ever-injectors for 109 drugs-related deaths and 
11,297 person-years of follow-up; and France’s heroin-user arrestees for only 125 
drugs-related deaths despite 39,618 person-years of follow-up. In sum, there were 709 
drugs-related deaths in 97,783 person-years during cohorts’ first two years of follow-
up. The much lower drugs-related death rate for France’s heroin-user arrestees is 
striking – and applies to other causes also, which could suggest under-ascertainment 
of deaths. 
 
Table 2 shows drugs-related deaths (also all non-HIV deaths), person-years of follow-
up, and drugs-related death-rate for the six EMCDDA combined, and separately for 
the two external cohorts by current age-group (15-24 years, 25-34 years, 35-44 years, 
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45+ years old) and gender. Trends in drugs-related death rate by current age-group did 
not appear particularly strong, but drugs-related death rate was higher for males than 
females, France’s heroin-user arrestees excepted. The combined non-HIV death-rate, 
on the other hand, shows consistent increase (over 60%) between current age-group of 
15-24 years versus 25-34 years, whether one looks at the six EMCDDA cohorts 
combined, or external cohorts from Scotland and France. 
 
Table 3 presents pooled Poisson regression analyses for the two external reference 
cohorts [1], for the six 1990s-recruited EMCDDA cohorts [2], and for all eight 
combined [3]. Drugs-related death rates were highest in Barcelona, followed by 
Denmark and Scotland, rates were comparable for Lisbon, Rome and Vienna, and 
lowest in Dublin and France (see Table 3: RR[3]). The six drug treatment cohorts and 
combined analysis confirmed a significantly higher risk of drugs-related deaths for 
males (see RR[3], 1.4 with 95% confidence interval from 1.2 to 1.6).  
 
By contrast, the EMCDDA cohorts gave little support for there being an increased 
risk of drugs-related death at older current age for clients at drug treatment agencies 
(see Table 3: RR[2] results), whereas the two external cohorts signalled that the 
relative risk of drugs-related death was significantly higher for heroin-user arrestees 
or HCV-diagnosed ever-injectors aged 35-44 years compared to under 25 years of age 
(see RR[1], 1.7 with 95% confidence interval from 1.2 to 2.5). Irrespective of 
recruitment setting, drugs-related death-rates were lower by the third or later epoch of 
follow-up. 
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Age at heroin initiation was available for most, but not all, clients from four 
EMCDDA cohorts (Rome, Barcelona, Lisbon and Denmark). With time since start of 
heroin career as the time-scale for proportional hazards analysis, higher drugs-related 
death rate for males (RR = 1.2; 95% CI: 1.0 to 1.5) and by injecting as primary route 
(RR = 1.6; 95% CI: 1.4 to 1.9) were confirmed. Against a backdrop whereby the 
underlying time-specific hazard of drugs-related death increased markedly from the 
second decade of a heroin career, the data were neutral on whether older current age-
group conferred a higher risk of drugs-related death (95% CI: 0.7 to 1.3). 
 
DISCUSSION 
As injectors increase their heroin consumption over time, the gap between tolerance 
of its euphoric effects and respiratory depression narrows (White and Irving, 1999), so 
that other tolerance-mediating factors (Warner-Smith et al., 2001; Best et al., 2000; 
Caplehorn et al., 1996; Preti et al., 2002; and Bird et al., 2001) - use of respiratory 
depressants, systemic disease, imprisonment, discharge from treatment, attempts to 
moderate use, unfamiliar environments or homelessness - may be more likely to 
precipitate an overdose.  Indeed, the reported sex difference (Bird et al., 2003) in risk 
of drugs-related death may be related to cofactors that elevate the risk of overdose, for 
example the use of other respiratory depressants, alcohol, rate of imprisonment, or 
homelessness; or may be intrinsic. 
 
Internationally, and confirmed in this analysis, the risk of drugs-related death is 
substantially higher for injecting drug users compared to non-injecting opiate users 
(Preti et al., 2002 and Darke, Degenhardt and Mattick, 2007); and substantially lower 
for opiates users receiving substitution treatment (Mattick and Degenhardt, 2003).  
 15 
Differences in the proportion of current injectors by age, or of opiate users in 
treatment, may explain differences between countries, or account for cohorts’ ranking 
in terms of drugs-related death rates. The main virtue of a combined analysis, as 
reported here, is therefore not international league tables, but to identify influences on 
drugs-related deaths which are broadly consistent across a range of regional and 
enrolment settings. When the label “injector” refers, as here, either to ever-injectors or 
to users who primarily injected, the associated relative risk (1.6; 95% CI 1.4 to 1.9) 
will tend to under-estimate the drugs-related death risk associated with current 
injecting. 
 
Consistency has been borne out across the eight cohorts in respect of male heroin 
users’ or injectors’ 1.4 times higher age-specific risk of drugs-related death (95% CI: 
1.2 to 1.6), see also cross-sectional synthesis of national data from member state in 
European Union (below). Back-calculation of past incidence for heroin use/injecting 
should take into account males’ 1.4 times higher age-specific risk of drugs-related 
death (Bargagli et al., 2005); and a forteriori for all non-HIV deaths, see Table 2. 
 
Synthesis of national data for 10 European countries (EMCDDA, 2003), in which the 
age distribution of two recent years’ drugs-related deaths (mainly 2000+2001) was 
compared to the age-distribution of new clients at drug treatment agencies, found a 
median relative risk of drugs-related death of 2.4 for problem drug users aged 35+ 
years versus younger, see Table 4. This contrasts markedly with the influence of 
current age that emerges from our within-cohort analyses which failed strongly to 
convince that the drugs-related death-rate is higher for heroin users/ever-injectors 
aged 35-44 years versus under 25 years (RR: 1.2 with 95% CI from 0.95 to 1.42).  
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Different cohort-recruitment biases by sex and age or different physiological or 
pathological mechanisms (in, or out of treatment) may explain the better concordance 
for the influence of sex (versus current age) on the risk of drugs-related death between 
national data synthesis and cohorts’ analyses. For example, greater alcohol 
consumption by males, and associated risk for overdose death, may be an enduring 
phenomenon in and out of treatment settings (White and Irving, 1999; Warner-Smith 
et al., 2001; Best et al., 2000; Caplehorn et al., 1996; and Darke, Degenhardt and 
Mattick, 2007). 
 
Possible explanations with different practical, public health consequences are: a) older 
heroin users and injectors are relatively under-represented as new clients at drug 
treatment agencies compared to nationally, which inflates older users’ apparent drugs-
related death rate in synthesis of national data sources; or b) enrolment at a drug 
treatment (versus other) agency effectively mitigates an otherwise-high drugs-related 
death rate for heroin users or injectors aged 35 years or older in the outside 
community. If true, mitigation of age-related hazard of drugs-related death could be 
an additional benefit of recruitment into drugs treatment for older opiate users – but 
differential age effect was not substantiated by a data-inspired test for interaction by 
cohort (external versus EMCDDA).  
 
Even the upper 95% confidence limit of 2.5 for relative risk (35-44 years versus under 
25 years) in the two externally-recruited cohorts conveys a more moderate impression 
of the influence of current age than the national data syntheses in Table 4, and is 
sufficient to rule out an extreme influence of current age such as six times higher risk 
(Bird et al., 2003) for heroin users or ever-injectors aged 35+ years.  
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Our results mean that back-calculations which assume constant relative risk by age of 
drugs-related death (Law et al., 2003 and Hutchinson et al., 2005) cannot be gainsaid, 
but the external cohorts (and national data syntheses) admit of the possibility that the 
age-related risk could be 2.5 times higher for heroin users aged 35+ years. De Angelis 
et al. (2004) have shown that relative risks of even this magnitude have major 
consequences for back-calculated inferences about injector incidence in past decades. 
That males’ risk of drugs-related death is 1.4 times higher than for females should be 
taken into account in back-calculations, even if the hazard of drugs-related death is 
unaffected by current age. Moreover, back-calculations need to take into account that 
opiate-users, like ex-prisoners (Bird and Hutchinson, 2003 and Singleton et al., 2003), 
have about five times their age-appropriate risk of dying from other causes than HIV 
and drugs-related (Bird and Hutchinson, 2003).  
 
Although the purpose of the COSMO Workshop was not to create an international 
league-table of drugs-related death rates, we should be remiss if we did not remark 
upon the marked inter-cohort heterogeneity in Table 3 – so much so that member 
states would do well to document the mortality by date and cause for all who are 
referred to their drug treatment agencies. 
 
Recruitment of nearly 6000 clients is needed to observe around 100 drugs-related 
deaths in the first two years of follow-up. More extended follow-up risks that clients’ 
enrolment characteristics no longer represent current drug-dependency or route of 
administration. Thus, database linkage studies which do not intend to follow-up 
individual clients should be powered on the number of drugs-related deaths expected 
within at most two years of enrolment; should establish age at first use of heroin, and 
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age at starting to inject; and should enter data immediately so that programmed 
logical checks can be made when the client is present which enables inconsistencies 
to be resolved immediately. 
 
Across our eight cohorts, deaths from other causes (excluding HIV) approximately 
equalled the number of drugs-related deaths. Other papers in this series put the 
COSMO Workshop in wider context and report standardized mortality ratios by 
gender, and gauge the fraction of overall mortality at ages 15-49 years which is 
accountable to opiate users, see Bargagli et al., 2005. 
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Table 1: Cohorts at a glance 
Cohort All 
Clients;  
male 
clients 
(%) 
Recruitment 
Period; & 
number of 
clients (%) 
enrolled in 
1997+ 
Last follow-
up date; & 
deaths by 
cause:  
DRDs, HIV,  
 other,    nk  
Analysis 
horizon of 2 
years: person-
years & number 
of drugs-related 
deaths (DRDs) 
Number of clients 
(%) with 
enrolment age 
under 20 years;   
  over 39 years 
France’s heroin 
arrestees: 
enrolment date 
= 1 January in 
year after arrest 
19976; 
16432 
(82.3%) 
 
1992-1993 & 
1996-1997; 
16393 (82.1%) 
31 Dec 1999;  
181,  58,      
197,   17 
39618 pys    & 
     125 DRDs 
 
1251 (6.3%); 
  465 (2.3%) 
Scotland’s ever-
IDUs, enrolled at 
HCV diagnosis* 
date + 28 days 
  6840; 
  4876 
(71.3%) 
 
1993-2001; 
4869 (71.2%) 
31 Dec 2001; 
195, 115,  
221,     0 
11297 pys    & 
    109 DRDs 
  
 319  (4.7%); 
 626  (9.2%) 
Barcelona: [ever-
IDU status - not 
currently available] 
  5039; 
  3853 
(76.5%) 
 
1992-1997; 
  480 ( 9.5%) 
 
{includes 25 
enrolments in 
1991} 
31 Dec 2001;  
395, 428,      
271,   58 
  9409 pys    & 
     207 DRDs 
 
 224 ( 4.4%); 
 293 ( 5.8%) 
Lisbon’s 
primary opiate 
users: known 
IDUs = 760 
  3266; 
  2606 
(79.8%) 
 
1992-1997; 
 158 ( 4.8%) 
31 Dec 2001;  
122, 178,      
  91,   48 
  6440 pys    &  
      35 DRDs 
  
 408 (12.5%); 
   49 (  1.5%) 
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Rome’s heroin 
users: known 
IDUs = 4106 
  5924; 
  4876 
(82.3%) 
 
1992-1995; 
     0 ( nil%) 
31 May 1997;  
141, 135,      
142,     7 
11489 pys    & 
       94 DRDs 
 
 186  (3.1%); 
 269  (4.5%) 
Vienna   4152; 
  2898 
(69.8%) 
 
1990-1998; 
1251 (30.1%) 
31 Dec 1998;  
  98,  37,      
  60,    1 
  6939 pys    & 
       45 DRDs 
 
 373 ( 9.0%); 
 192 ( 4.6%) 
Dublin   5287; 
  3769 
(71.3%) 
 
1993-1997; 
1589 (30.1%) 
31 Dec 1997;  
  34,  24,      
  52,    4 
  7461 pys    & 
       26 DRDs 
 
1024 (19.4%); 
  140 (  2.6%) 
Denmark: [ever-
IDU status - not 
currently available] 
  3486; 
  2602 
(74.6%) 
 
1997-1999; 
3486 (100%) 
31 Dec 1999;  
  74,    3,      
  52,    6 
  5130 pys    & 
       68 DRDs 
 
 115 (  3.3%); 
 852 (24.4%) 
 
Footnotes* 
Scotland: recruitment was limited to 1993 onwards to minimise contamination by earlier HCV 
“diagnosis” dates which represented retrospective HCV testing of stored sera from later HCV-
diagnosed individuals. France & Lisbon: based on local knowledge, ill-defined deaths were classified 
as drugs-related. 
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Table 2: Drugs-related deaths (DRDs) and all non-HIV deaths by current age*; 
and drugs-related deaths by sex  
Drugs-related  All non-HIV  Causes  
Current age 15-24 25-34 35-44 45+ 15-24 25-34 35-44 45+ 
France 
Deaths 
PY at risk 
Rate per1000  
(95% CI) 
     34 
15602 
     2.2  
(1.4- 2.9) 
   117 
39394 
    3.0 
(2.4- 3.5) 
     29 
 8048 
    3.6 
(2.3– 4.9) 
       1 
   700 
    1.4  
(0.2-10.1) 
      72 
15602 
     4.6 
(1.8-  9.0) 
    247 
39394 
    6.3 
(3.7-  5.9) 
      69 
  8048 
     8.6  
(6.6-10.6) 
        7 
    700 
   10.0  
(4.8-21.0) 
Scotland  
Deaths 
PY at risk 
Rate per1000  
(95% CI) 
      27 
  3116 
     8.7  
(5.4-11.9) 
   108 
12399 
    8.7 
(7.1-10.4) 
     54 
 6053 
    8.9 
(6.5–11.3) 
       6 
 1026 
    5.8  
(2.6-13.1) 
       42 
   3116 
    13.5  
(9.4-17.6) 
    196 
12399 
   15.8  
(13.6-18.0) 
     131 
   6053 
    21.6  
(17.9-25.3) 
      40 
  1026 
   39.0 
(26.9-50.1) 
Six EMCDDA drug-treatment agency cohorts (summed) 
Deaths 
PY at risk 
Rate per1000  
(95% CI) 
    151 
20503 
     7.4  
(6.3- 8.6) 
    490 
59451 
     8.2 
(7.5- 9.0) 
    191 
23195 
     8.2 
(7.1- 9.5) 
     31 
 2981 
  10.7  
(7.0-14.5) 
    237 
20503 
   11.6  
(10.2-13.1) 
    869 
59450 
   14.6 
(13.7-15.6) 
    434 
23195 
   18.7 
(17.0-20.6) 
   116 
 2981 
  38.9  
(31.8-46.0) 
Drugs-related deaths by sex Females Males 
France 
DR deaths 
PY at risk 
Rate per1000  (95% CI) 
           37 
     11177 
          3.3   ( 2.2 –  4.4) 
           144 
       52570 
            2.7   ( 2.3 – 3.2) 
Scotland 
 31 
DR deaths 
PY at risk 
Rate per1000   (95% CI) 
            42 
        6459 
           6.5  ( 4.5 –  8.5) 
            153 
        16211 
             9.4  ( 7.9- 10.9) 
Six EMCDDA drug-treatment agency cohorts (summed) 
DR deaths 
PY at risk 
Rate per1000  (95% CI) 
          157 
      24785 
           6.3  ( 5.4 –  7.4) 
            707 
        81367 
             8.7   ( 8.1-  9.4) 
* Footnote: Current age 15-24 =  from “15th birthday plus 1 day” to 25th birthday; results sensitive to 
cut-point; minor discrepancies in totals compared by sex and current age 15+. 
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Table 3: Poisson regression limited to current age < 45 years: Scotland and 
France [1]; for drug treatment cohorts [2]; and pooling of all cohorts [3]. 
Overall 
Scotland and 
France [1] 
Drug Treatment 
Cohorts [2] 
 Pooling all cohorts [3] 
Follow-up     
Cohorts 
 
Covariate Relative Risk, RR (95% CI) 
Male 1.17 (0.90 – 1.51) 1.46 (1.22 – 1.75) 1.36 (1.17 – 1.58) 
Current age 25-34 1.46 (1.04 – 2.05) 1.07 (0.87 – 1.32) 1.17 (0.98 – 1.40) 
Current age 35-44 1.72 (1.18 – 2.51) 0.99 (0.78 – 1.25) 1.16 (0.95 – 1.42) 
Barcelona  Baseline Baseline 
Lisbon  0.39 (0.31 – 0.48) 0.40 (0.32 – 0.49) 
Rome  0.40 (0.33 – 0.48) 0.40 (0.33 – 0.49) 
Vienna  0.44 (0.35 – 0.55) 0.44 (0.35 – 0.56) 
Dublin  0.19 (0.13 – 0.27) 0.19 (0.13 – 0.28) 
Denmark  0.66 (0.50 – 0.88) 0.66 (0.50 – 0.88) 
              France Baseline  0.17 (0.14 – 0.21) 
              Scotland 3.11 (2.52 – 3.84)  0.58 (0.48 – 0.69) 
2nd  follow-up epoch 
(2nd six months of 
follow-up) 
0.90 (0.71 – 1.14) 0.72 (0.61 – 0.85) 0.77 (0.67 – 0.88) 
3rd or later 6-month 
epoch 
0.42 (0.29 – 0.61) 0.44 (0.36 – 0.53) 0.44 (0.37 – 0.52) 
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Table 4: Synthesis from European Monitoring Centre for Drugs and Drug 
Addiction Annual Report 2003  
Drugs-related deaths [D] Problem drug users 
initiating treatment [P] 
 
 
Member State 
& population 
aged 15-64  
(in millions) 
In two 
years: 
mainly 
2000+01 
% male 
[Dm] 
% 35+ 
years old 
 [Dold] 
% male   
[Pm] 
% 35+  
years old 
[Pold] 
Male 
users’  
RR of 
drugs-
related 
death 
Older  
users’ 
RR of 
drugs-
related 
death 
Austria       5.5    306 84% 37% 72% 19.7%   2.0   2.4 
Denmark    3.5    505 82% 61% 77% 21.8%   1.4   5.6 
Finland       3.4    140 84% 19% 73%   6.6%   1.9   3.3 
Germany   55.1  3865 84% * 80%   9.6%   1.3      * 
Greece        7.1    625 93% 23% 86% 17.8%   2.2   1.4 
Ireland        2.3    233 76% 45% 77%   7.0%   0.9 10.9 
Italy          39.0  1841 89% 42% 87% 42.7%   1.2   1.0 
Netherl.    10.7    174 85% 53% 80% 31.0%   1.4   2.5 
Portugal     6.9    598 90% 28% 83% 28.0%   1.8   1.0 
Spain        27.2    494 82% 49% 85% 23.9%   0.8   3.1 
Sweden      5.6    205 85% 47% 64% 31.1%   3.2   2.0 
Median RR        1.4   2.4 
Pooled  RR        1.4   2.4 
England & 
Wales  ~   35.0        
 
3286 
 
81% 
 
41% 
 
* 
 
* 
 
    * 
     
     * 
France      38.1    226 90% 28% 80% 42.0%   2.2   0.5 
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Footnote 1: Dm denotes the percentage male among drugs-related deaths, Dold the 
percentage older than 35 years; Pm denotes the percentage male among problem drug 
users who initiated treatment, Pold is the percentage aged than 35 years or older 
among treatment initiates. Relative risk, RR, of drugs-related death for males versus 
females was approximated by  
Relative Risk (males) = Dm/Pm * [100-Pm]/[100-Dm]; 
and for older versus younger problem drug users by  
Relative Risk (older) = Dold/Pold * [100 – Pold]/[100-Dold]. 
Data from France are presented, but not included in the weighted summary of 
observed relative risks, which uses the number of drugs-related deaths as weighting. 
Footnote 2: with acknowledgement to data providers in member states for source 
Statistical Tables 7, 24 and 25; * indicates not available; Spain’s 494 drugs-related 
deaths pertained to five cities only with population of 4.2 millions aged 15-64  years. 
 
